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Effects of BQ-123 on renal function and acute cyclosporine-induced
renal dysfunction. Cyclosporin A (CsA) is widely used to suppress graft
rejection following transplantation and in the treatment of a variety of
autoimmune diseases. Therapy with CsA is often accompanied by
adverse effects which include hepatotoxicity, hypertension, and neph-
rotoxicity. The role of endothelin (Et) in CsA-induced nephrotoxicity
has been the subject of recent investigations. BQ-123 is a recently
discovered Et receptor antagonist which is selective for the EtA
receptor. In the present study, BQ-123 was used to further characterize
the role of Et in CsA-induced nephrotoxicity. All experiments were
performed in mactin (100 mg/kg, i.p.) anesthetized male Munich-Wistar
rats (250 to 350 g). Animals were prepared for the recording of blood
pressure (MAP) and heart rate (HR) as well as the measurement of urine
volume (UV), UNaV, UKV, GFR and effective renal plasma flow
(ERPF). GFR and ERPF were estimated from the clearance of '4C-
inulin and 3H-PAH, respectively. On the day of the experiment, animals
were randomly assigned to one of three groups and treated according to
the following protocols: Group 1, pretreatment with BQ-123 (1 mg/kg,
i.v. bolus with 0.1 mg/kg/hr i.v. infusion) followed by treatment with
vehicle (creinophor; 0.15 ml, i.v.); Group 2, pretreatment with normal
saline (1.0 mI/kg; plus 25 p1/mm infusion) followed by treatment with
CsA (20 mg/kg, i.v.); and Group 3, pretreatment with BQ-123 (same as
group 1) followed by CsA (20mg/kg, i.v.). BQ-123 administration alone
produced transient changes in several of the measured parameters.
These transient changes included reductions in both ERPF (—1.1
ml/min/lOO g, P  0.01 vs. baseline = 2.7 0.1) and GFR (—0.3
mlJminIlOO g, P 0.01 vs. baseline = 0.9 0.04). In contrast, ifitration
fraction (FF) and UNaV were increased. By forty minutes after admin-
istration of BQ-123, the measured parameters of renal function returned
to control values and remained stable for the experimental period. CsA
alone significantly increased MAP (+ 14 mm Hg, P  0.05 vs. baseline
127 3) and reduced ERPF (—0.9 ml/min/100 g, P  0.01 vs. baseline
= 2.6 0.2) and GFR (—0.2 ml/min/100 g, P  0.01 vs. baseline = 0.9
0.05). Administration of CsA also produced reductions in UV and
UKV, and there was a tendency toward reduction in UN8V. In the
presence of BQ-123, the effects of CsA on MAP, ERPF and GFR were
completely prevented. However, BQ-123 failed to prevent CsA-induced
changes in UV, UNaV and UV. The present data demonstrate that
BQ-123 itself causes transient changes in ERPF, GFR and tubular
function which may be explained by a partial agonist effect of this
compound. Additionally, systemic pretreatment with BQ-123 prevented
CsA-induced changes in MAP, ERPF and GFR but did not prevent
changes in UV, UNaV and UKV. Therefore, when given intravenously
prior to CsA BQ-123 can prevent the hypoperfusion and hypofiltration
associated with CsA-induced nephrotoxicity; however, tubular medi-
ated processes appear to remain at risk.
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Cyclosporine A (CsA) is now widely used clinically to
suppress graft rejection following transplantation of the heart,
lungs, and kidneys [1—3]. CsA is also widely used in the
treatment of autoimmune diseases [4]. The frequency and
length of treatment with CsA has revealed a variety of side
effects that accompany therapy with CsA. These adverse ef-
fects include hepatotoxicity, hypertension, and nephrotoxicity
[4, 5]. CsA-induced nephrotoxicity can range in severity from
an early, acute reversible decrease in glomerular filtration rate
(GFR) to a progressive irreversible chronic renal failure [5]. It is
now well-documented that the initiating event in CsA-induced
nephrotoxicity is an intense vasoconstriction. The exact agent
responsible for the vasoconstriction is not known; however,
several possibilities have been suggested including the sympa-
thetic nervous system [6], the renin-angiotensin system [7], and
antidiuretic hormone [7]. Additionally, CsA has also been
shown to cause endothelial cell damage [8] which may then lead
to the elaboration of the potent vasoconstrictor endothelin [9].
Endothelin (Et) has been shown to have dramatic effects on
renal hemodynamics and function. In rat and dog, the intrave-
nous administration of Et has been shown to cause a dose-
dependent increase in renal vascular resistance and a decrease
in both renal blood flow and glomerular filtration rate [10, 11,
12]. These studies have also shown that following the adminis-
tration of exogenous Et urine flow, urinary sodium excretion
and fractional excretion of sodium are reduced. These adverse
effects of Et on renal hemodynamics and function are similar to
the changes seen early in the course of CsA-induced nephro-
toxicity [5].
The role of Et in CsA-induced nephrotoxicity has been the
subject of recent investigations. In the intact rat as well as in an
isolated rat kidney preparation, pretreatment with an anti-
endothelin antibody prevented CsA-induced decreases in renal
blood flow, glomerular ifitration rate, and renal perfusate flow
[13]. Using micropuncture techniques, Kon et al have demon-
strated the reversal of CsA-induced glomerular dysfunction by
treatment with an anti-endothelin antibody [14]. These investi-
gators also demonstrated an approximate tenfold increase in the
plasma concentration of Et following CsA administration in the
rat. Taken together, the studies cited above provide compeffing
evidence that endothelin is involved in CsA-induced nephro-
toxicity.
The recent discovery of BQ-123, an endothelin receptor
antagonist selective to the EtA receptor [15], has allowed
further investigation into the role of Et in CsA-induced renal
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dysfunction. BQ-123 has recently been shown to protect the
kidney from CsA toxicity [16]. Protection was only observed,
however, when BQ-123 was administered directly into the renal
artery. This finding suggested that for BQ-123 to be effective
against CsA-induced nephrotoxicity it would have to be given
directly into the renal circulation or at high doses intravenously,
either of which may limit the clinical usefulness of BQ-123.
Therefore, the present study describes the efficacy of BQ-123
administered intravenously at a relatively low dose to prevent
the acute changes in renal function during CsA administration.
Methods
Experiments were performed on male Munich-Wistar rats
weighing 250 to 350 g. All animals were allowed free access to
standard rat chow and tap water until the day of the experiment.
The morning of the experiment animals were anesthetized with
mactin (100 mg/kg body wt. i.p.). An indwelling polyethylene
catheter was placed in the right carotid artery for the collection
of blood samples and the continuous measurement of systemic
blood pressure and heart rate via a Cobe transducer and
recorded on a Grass model 7D Physiologic recorder. Two
catheters (PE-SO) were also inserted into the right jugular vein
and a single catheter into the left femoral vein for blood
sampling, the infusion of inulin, p-aminohippuric acid (PAH),
CsA, CsA vehicle, or saline. A suprapubic incision was made
and the urinary bladder was catheterized (PE-90). An infusion
of 14C-inulin (0.1 sCi/ml) and 3H-PAH (2.0 sCiIml) in normal
(0.9%) saline at a rate of 25 pilmin was begun immediately. A
separate infusion of normal saline (25 p1/mm) was also begun.
The animals' body temperature was maintained at 37°C via a
heating pad. A one hour stabilization/equilibration period was
allowed prior to the initiation of any experimental protocols.
Following the stabilization/equilibration period three 20-
minute control clearances were recorded for each animal. The
animals were then randomly assigned to one of three experi-
mental groups.
Group I
Following the control clearances animals in group 1 received
BQ-l23 (1.0 mg/kg i.v., bolus followed immediately by 0.1
mg/kg/hr continuous infusion). Two 20-minute clearances were
recorded. At the end of this period, while the infusion of
BQ-123 continued, the vehicle for CsA (cremophor) was admin-
istered (0.15 ml, i.v.) slowly over ten minutes, after which three
20-minute clearances were recorded.
Group 2
Following the control clearances animals in group 2 received
normal saline (1.0 mI/kg bolus followed immediately by 25
p1/mm infusion), the vehicle for BQ-l23, and two 20-minute
clearances recorded. Animals in group 2 were then treated with
CsA (20 mg/kg i.v.: Sandoz Pharmaceutical Co., East Hanover,
New Jersey, USA) given slowly over ten minutes. Three
20-minute clearances were then recorded.
Group 3
Following the control clearances animals in group 3 received
BQ-123 (exactly as described for group 1) and two 20-minute
clearances were recorded. These animals then received CsA (20
mg/kg, i.v. over 10 mm) and three 20-minute clearances were
recorded.
Therefore, all animals were monitored during three study
periods, a 60 minute control, a 40 minute equilibration, and a 60
minute experimental period. To determine the efficacy of Et
receptor blockade by BQ-123, the pressor response to an
exogenous Et-l (1.0 nmol/kg body wt., i.v., bolus) challenge
was measured in each animal at the end of the final period.
Glomerular filtration rate and effective renal plasma flow
were estimated according to the renal clearance of 14C-inulin
and 3H-PAH, respectively. Briefly, as described above, an
infusion of '4C-inulin and 3H-PAH was begun and the animals
allowed to equilibrate for 60 minutes. Each clearance period
consisted of a 20-minute urine collection, into a tared vial, with
a blood sample (150 p1/arterial) taken at the midpoint. Blood
and urine samples were centrifuged (Eppendorf model 5415 C)
and 50 p1 of plasma or urine were separately added to a 10-nil
liquid scintillation cocktail (Beckman Ready-Safe, Beckman
Instruments, Irvine, California, USA). Samples were counted
for 10 minutes in a liquid scintillation counter (Beckman model
LS 3201). Urine concentrations of sodium and potassium were
determined by flame photometry (IL 943, Instrumentation
Laboratories, Lexington, Massachusetts, USA). Plasma levels
of immunoreactive Et-l were measured in two separate groups
of animals (due to the amount of blood required to measure
Et-l) treated with either cremophor or CsA exactly as described
previously. One hour after treatment with either cremophor or
CsA two 2.5-ml blood samples were drawn, in series, and
placed into pre-chilled test tubes containing sodium heparin
(Vacutainer, Becton Dickinson, Rutherford, New Jersey, USA)
and the plasma concentration of Et-l measured by radioimmu-
noassay employing a commercially available kit (Amersham
Corporation, Arlington Heights, illinois, USA). All measure-
ments were made in duplicate.
Statistical analysis
All data are expressed as mean standard error. Differences
between experimental periods within a group were compared
by Dunnett's t-test [17]. Differences between groups were
tested by analysis of variance [18]. Results were taken as
statistically significant at P  0.05.
Results
Effects of BQ-123 on mean arterial pressure (MAP) and renal
function
The animals in groups 1 (N = 5) and 3 (N = 9) were exposed
to identical experimental conditions during control clearances
and administration of BQ-l23 prior to administration of cremo-
phor or CsA respectively. This allowed us to combine the data
from these animals (N = 14) to determine the effect of BQ-123
on MAP and renal function. Baseline values for MAP (135 2
mm Hg) and hematocrit (50 0.7%) were slightly elevated in
these animals. Heart rate was normal (402 10beats/mm). The
results of the three 20-minute control clearance measurements
were averaged to give the following baseline values for renal
function: effective renal plasma flow (ERPF = 2.7 0.1
mlJminIlOO g body wt), glomerular ifitration rate (GFR = 0.9
0.04 mI/min/lOO g body wt), urine volume (UV = 41 7
mi/mm), filtration fraction (FF = 35 1%), urine sodium
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Table 1. The effect of intravenous administration of BQ-l23 (1 mg/kg
bolus, followed by 0.1 mg/kg/hr) on mean arterial pressure (MAP),
effective renal plasma flow (ERPF) and glomerular filtration rate
(GFR) in the mactin anesthetized rat
MAP
mm Hg
ERPF GFR
mi/min/JOO g
Control 135.0 2.0 2.70 0.10 0.90 0.04
20 mm 129,6 2.2" 1.62 0.15" 0.63 0.06"
40 mm 131.0 1.9k 2.40 0.16 0.85 0.05
ERPF and GFR were estimated from the clearance of 3H-PAH and
'4C-inulin, respectively. The data are the mean SEM (N = 14).
aP  0.05; "P 0.01
excretion (UNaV = 3.4 0.7 sEq/min) and urine potassium
excretion (UKV = 3.6 0.2 Eq/min). Twenty minutes after
initiation of BQ-123 (1.0 mg/kg bolus plus 0.1 mg/kg/hr) MAP
was mildly although significantly reduced (Table 1). In addition
to MAP, both ERPF and GFR were also significantly reduced
(Table 1). Despite the reduction in MAP, ERPF and GFR; FF
and UNaV were increased 40 2% (P 0.01 vs. baseline) and
5.1 0.9 pEq/min (P 0.01 vs. baseline), respectively. These
acute changes in renal function were transient. By the end of
the second clearance period, 40 minutes after the start of
BQ-123, the measured parameters of renal function had re-
turned to values which were not statistically different from
control: ERPF = 2.4 0.16 mllmin/100 g, GFR = 0.85 0.05
mi/mm/tOO g, FF = 36 2% and UNaV = 4.1 0.5 p.Eq/min.
In contrast MAP remained slightly reduced (131 1.9 mm Hg,
P 0.05 vs. baseline). Time control experiments demonstrated
that these values did not change during an additional one hour
of BQ-123 administration (data not shown).
Group I
The effect of the CsA vehicle (Cremophor) on MAP and renal
function in the presence ofBQ-123. In the presence of BQ-123,
cremophor appeared to have profound effects on tubular func-
tion independent of changes in renal hemodynamics. Cremo-
phor administration had no effect on MAP (133 2 vs. 136 5
mm Hg), ERPF (2.4 0.1 vs. 2.3 0.1 ml/min/lOO g) or GFR
(0.9 0.05 vs. 0.9 0.04 mllmin/100 g) in these animals (Fig.
1). Whereas these parameters were not changed, cremophor
administration produced significant increases in UV (31 6 vs.
61 8 4/mm), UNaY (5.4 0.2 vs. 11.5 0.3 Eq/min) and
UKV (3.6 0.3 vs. 4.0 0.2 jsEqlmin) as shown in Figure 2.
Group 2
The effects of CsA on MAP and renal function. The animals
in this group were pretreated with normal saline, the vehicle for
BQ-123, prior to administration of CsA. Saline administration
had no effect on MAP (128 2 vs. 127 3 mm Hg), HR (391
17 vs. 378 12 beats/mm) or hematocrit (50 0.3 vs. 50
0.4%), control versus 40 minutes of saline administration. In
addition, ERPF (3.1 0.2 vs. 2.6 0.2 mlIminIlOO g), GFR (1.0
0.08 vs. 0.9 0.05 ml/min/100 g), FF (33 1 vs. 35 3%),
and UKV (4.1 0.7 vs. 4.0 0.4 EqImin) also remained
unchanged. In this group of animals saline administration
increased UV (20.7 6 vs. 57 10 p1/mm) and UNaV (2.7 1
vs. 6.6 2 p.Eq/min). Previous experiments conducted in our
laboratory have shown that these parameters remain stable for
Fig. 1. Prevention of GsA-induced changes in mean arterial pressure
(MAP), effective renal plasma flow (ERPF) and glomerular filtration
rate (GFR) by intravenous pretreatment with BQ-123 (see text for
details). Symbols are: () BQ-123 + Cremaphor (N = 5); (P4) saline +
CsA (N = 4); () BQ-l23 + CsA (N = 9). Statistical significance *JJ 
0.05; ** 0.01.
three hours during saline infusion. Forty minutes after the start
of saline infusion and measured parameters had stabilized, CsA
was administered intravenously. GsA administration caused a
significant increase in MAP (127 3 to 141 5 mm Hg; Fig. 1)
without a change in HR (data not shown). The increase in MAP
was accompanied by reductions in both ERPF (2.6 0.2 to 1.7
0.1 ml/min/100 g) and GFR (0.9 0.05 to 0.7 0.04
ml/min/100 g) of 35% and 22%, respectively (Fig. 1), indicating
a marked increase in renal vascular resistance. In keeping with
the hemodynamic changes UV (57 10 to 29 5 mlimin) and
UKV (4.0 0.4 to 2.7 0.3 jsEq/min) were also significantly
reduced (Fig. 2). Although not significant, there was also a
trend toward a reduction in UNaV as shown in Figure 2.
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Fig. 3. Change in mean arterial pressure (MAP) following an intrave-
nous challenge with endothelin-1 (Et-1; 1.0 nmol/kg) during control
conditions and in the presence of BQ-123 (1.0 mg/kg bolus followed by
0.1 mg/kg/Fir) at the end of the experimental period. The data are the
mean SEM (N = 5); statistical significance *p  0.05.
Efficacy of endothelin receptor blockade by BQ-123
I
Fig. 2. Failure of BQ-123 to prevent CsA-induced changes in urine
volume (UV), urine potassium excretion (UKV) and urine sodium
excretion (UN4V) (see text for details). Symbols are: (0) BQ-123 +
Cremaphor (N = 5); () saline + CsA (N = 4); (El) BQ-123 + CsA (N
= 9). Statistical significance *f 0.05; ** 0.01.
Group 3
The effects of CsA in the presence of BQ-123. CsA had no
effect on MAP (130 3 vs. 132 2 mm Hg), ERPF (2.4 0.3
vs. 2.1 0.2 ml/min/100 g) or GFR (0.8 0.06 vs. 0.8 0.07
mllmin/100 g) in the presence of EtA receptor blockade by
BQ-123 (Fig. 1). However, CsA did cause reductions in UV (33
5 to 16 1 piImin), UNaV (3.4 0.6 to 2.4 0.4 Eq/min)
and UV (3.1 0.2 to 2.2 0.2 jsEq/min) as shown in Figure
2. In a separate group of animals (N = 9) plasma levels of Et-1
were measured prior to and following CsA (20 mg/kg, i.v.). CsA
significantly increased circulating plasma levels of Et- 1 from 9.1
0.6 to 11.1 0.7 fmollml (22% increase above control).
In the present experiments, all animals that received BQ-123
were challenged with Et-l (1.0 nmol/kg, i.v.) following the final
clearance measurement. In these animals, Et-1 increased MAP
9 1 mm Hg in the presence of BQ-l23 (N = 14) compared to
an increase of 38 2 mm Hg during control conditions in a
separate group of animals (N = 5; Fig. 3).
Discussion
In the present study intravenous pretreatment with an EtA
selective endothelin receptor antagonist (BQ-123) protected the
kidney from CsA-induced hypoperfusion and hypoffitration.
CsA is now widely used in the clinical management of graft
rejection and various autoimmune diseases [1—4]. CsA therapy
is often accompanied by severe side-effects which include
nephrotoxicity [4, 5]. The frequency and severity of CsA-
induced nephrotoxicity may limit the clinical use of CsA [5].
The acute renal dysfunction observed after CsA administration
has been attributed to renal vasoconstriction which can be
reversed by administration of an anti-endothelin serum [14].
Recently, endothelin receptor blockade with BQ-123 was also
shown to protect the kidney from acute CsA toxicity when
administered directly into the renal artery [16]. The findings in
the present study, that BQ-123 administered intravenously at a
relatively low dose prevented the renal vasoconstriction and
hypoflltration following CsA administration, are encouraging
toward finding a clinically useful agent to prevent CsA nephro-
toxicity. In addition, the present study supports previous stud-
ies [14, 16] suggesting an important role for endothelin in
CsA-induced nephrotoxicity.
Important in understanding the role an endothelin receptor
antagonist might play in preventing CsA-induced nephrotoxic-
ity is an understanding of the effects of the antagonist itself on
renal function. To our knowledge this has not been described
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for BQ-123. In the mactin anesthetized Munich-Wistar rat
BQ-123 lowered MAP approximately 5 mm Hg. Control MAP in
these animals was 135 2 mm Hg which is slightly above the
normotensive range. It has been our experience that animals
anesthetized with mactin have elevated MAP, although others
have reported lower pressures using the same anesthetic agent
[14, 16]. In addition to lowering mean arterial pressure, BQ-123
also transiently reduced ERPF and GFR, both of which had
returned to a value not different from control at 40 minutes after
the start of BQ-123 administration. The other parameters of
renal function were not significantly influenced by BQ-123
although urine volume tended to increase at the 20 minute time
point and return to control by 40 minutes (data not shown).
Time control experiments demonstrated that all measured pa-
rameters were stable by 40 minutes after the start of BQ-123
infusion and remained stable for the study duration. The
transient changes may be accounted for by a bolus effect of
BQ-123. The decrease in both ERPF and GFR suggest an
increase in afferent arteriolar resistance, similar to that seen
following administration of Et-1 [12]. These findings suggest a
possible partial agonist effect of BQ-123 following the bolus
dose. Additionally, the tendency for urine volume to increase
following the bolus of BQ-123 also suggests a partial agonist
response in as much as Et-1 has been reported to directly inhibit
sodium and water reabsorption [19, 20]. The fact that MAP did
not increase in the present study following the bolus of BQ-123
may be a result of increased sensitivity of the renal vasculature
and tubules compared to the systemic vasculature. Recently,
Cristol et al have reported a differential sensitivity to endothelin
agonists (endothelin-1, endothelin-3, sarafotoxin 6b and sarafo-
toxin 6c) when comparing the systemic pressor response to
renal vasoconstriction [21]. In fact two independent locally
acting systems for endothelin have been proposed within the
kidney [20]. Because the dose of BQ-123 employed in the
present study was effective in blocking the response to exoge-
nous Et-l (increase in MAP) for the entire experimental period,
a full dose response curve to BQ-123 was not done. However,
given the present findings, a study designed to look specifically
at the effects of BQ- 123 on renal function across a dosing range
certainly seems wananted.
The administration of CsA is known to result in cellular injury
and the release of endothelin, resulting in a prompt increase in
circulating Et-1 levels [5]. This increase in circulating Et-1
levels is associated with an increase in systemic and renal
vascular resistance. The intravenous administration of CsA
alone, in the present study, produced significant changes in
MAP, ERPF and GFR. Mean arterial pressure was increased
while both ERPF and GFR were decreased. These changes are
similar to those reported by other investigators [14, 16]. In
addition to the changes mentioned above CsA also significantly
reduced urine volume and UKV. There was also a tendency for
UNaV to decrease; however, statistical significance was not
achieved. The intravenous administration of BQ-123 prior to
CsA prevented the CsA-induced changes in MAP, ERPF and
GFR. The ability of BQ-123 to block CsA-induced acute
changes in renal hemodynamics and filtration has been reported
previously [16]. However, in the study of Fogo et al [161,
BQ-123 was effective only when administered directly into the
renal circulation prior to CsA. When administered systemically
(intravenously) as a continuous infusion without a bolus loading
dose, BQ-123 failed to protect the kidney from acute CsA-
induced hypoperfusion and hypofiltration [16]. In the present
study BQ-123 was administered as a bolus plus an infusion. The
findings of the present study demonstrate that renal protection
against the acute reductions in ERPF and GFR can be achieved
by the intravenous administration of an endothelin antagonist
prior to administration of CsA. This finding may prove impor-
tant in as much as dosing directly into the renal artery would not
be practical for most clinical situations. The reason(s) for the
difference between our findings and those of Fogo et al [16] are
unclear. One possible explanation may be the way in which
BQ-l23 was administered. In the present study the bolus may
have provided a high concentration of drug to the receptor
which was then maintained by the infusion.
Prevention of the acute hemodynamic changes following CsA
administration is certainly important; however, an interesting
finding in the present study was that urine volume, UNaV, and
UKV all decreased following CsA in the presence or absence of
endothelin receptor blockade with BQ-123. When expressed as
a percentage decrease from baseline, these parameters were
reduced by an equal amount despite the prevention of CsA
effects on ERPF and GFR during BQ-123. Recently Hughes,
Cline and Kohan [20] proposed the existence of two locally
acting systems for Et-1 in the rat kidney: the first is responsible
for modulation of vascular smooth muscle tone and the second
for regulation of sodium and water excretion. This later Et-l
system is proposed to involve nephron derived Et-1 acting in
autocrine fashion to inhibit the reabsorption of sodium and
water. With this in mind, the reduction in urine volume and
UNaV following CsA administration is most probably related to
the reduction in GFR. The failure of BQ-123 to prevent CsA-
induced decreases in urine volume and UNaV may be explained
by a failure of BQ-123 to access sites, presumably in the inner
medullary collecting duct, responsible for Et-1 mediated diure-
sis and naturesis. An alternate explanation may be that these
effects not prevented by pretreatment with BQ-123 (EtA-selec-
tive) are mediated via the Et8-receptor.
In the present study, endothelin receptor blockade (EtA) with
BQ-123 caused transient changes in renal hemodynamics and
function. Intravenous pretreatment with BQ-123 prevented
CsA-induced reductions in renal hypoperfusion and hypofiltra-
tion but did not prevent the decreases in urine volume, UNaV
and UKV associated with CsA administration. While preven-
tion of the vascular changes associated with acute renal CsA
toxicity is encouraging, the lack of effect on tubular mediated
function may be of concern. Therefore, these data support a
role for endothelin in CsA-induced acute renal dysfunction and
suggest that the vascular and tubular effects may be differen-
tially mediated.
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